Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp85 | Diabetes (1) | ECE2016

Impaired RBC deformability is associated with pancreatic beta cell dysfunction and diabetic retinopathy in patients with type 2 diabetes

Sung Yoon Ji , Jin Kim Ho , Sung Moon Jun , Eun Lee Ji , Chang Won Kyu , Woo Lee Hyoung

Red blood cell (RBC) deformability is an ability of RBC to change shape under stress, and it has been known to be decreased in diabetes. However, the role of RBC deformability is not determined in type 2 diabetes (T2D) yet. We attempted to clarify whether RBC deformability is related with diabetic complications. This was a cross-sectional study, and 452 T2D patients were enrolled. RBC deformability was measured by using a microfluidic ektacytometer, Rheoscan-D (Rheo-Meditech, ...

ea0041ep644 | Endocrine tumours and neoplasia | ECE2016

A case of recurred parathyroid carcinoma with multiple lymph node metastasis: concurrent with papillary thyroid cancer

Woo Lee Hyoung , Jin Kim Ho , Sung Moon Jun , Sung Yoon Ji , Chang Won Kyu , Eun Lee Ji

Parathyroid carcinoma, a rare endocrine malignancy, accounting for only 1–2% of patients with primary hyperparathyroidism (HPT). In addition, a few case have been reported coexistence of parathyroid carcinoma and papillary thyroid cancer. Here, we present a case of recurred parathyroid cancer with multiple lymph node metastasis. A 57-year-old women was presented with high serum calcium level (14.4 mg/dl) in medical check-up. Hyperparathyroidism was considered to be the re...

ea0037ep585 | Obesity and cardiovascular endocrinology | ECE2015

Anti-obesity effect of Aster spathulifolius Maxim extract

Cho In-Jin , Choung Se Young , Kim Do Un , Hwang You-Cheol , Ahn Kyu Jeung , Chung Ho Yeon , Jeong In-Kyung

Purpose: Aster spathulifolius Maxim is one of plants of chrysanthemum, which has shown an anti-obesity activity in diet induced mice model. We performed clinical trial for evaluating the anti-obesity efficacy and safety of Aster spathulifolius Maxim extract on obese human.Methods: This study was randomised, double-blind, placebo-controlled clinical trial in Korea. A total of 41 obese subjects (BMI 25–30 kg/m2) aged ≥20 years were ra...

ea0014p224 | (1) | ECE2007

Effects of PGC-1α on endothelial function and apoptosis

Park Joong-Yeol , Won Jong Chul , Lee Ki-Up , Lee Woo Je , Ko Kyung Soo , Song Kee-Ho , Lee In-Kyu

Aims: Central obesity is associated with increased cardiovascular morbidity and mortality. It has been proposed that increased lipid accumulation in vascular tissue and the consequent increase in oxidative stress may be a missing link between obesity and atherosclerosis. The peroxisome proliferators-activated receptor (PPAR)-γ coactivator 1-α (PGC-1α) is a transcriptional coactivator playing an important role in energy metabolism. PGC-1α is present in vascu...

ea0056gp81 | Diabetes Complications | ECE2018

Impaired cortisol and growth hormone counterregulatory responses during severe hypoglycemia in type 2 diabetes mellitus

Rhyu Young A , Jang Ju-Young , Park Sooyoun , Kim Yoonjung , An Jee Hyun , Kim Dong-Lim , Kim Suk Kyeong , Song Kee-Ho

Background: Cortisol and growth hormone elevations are critical counterregulatory responses to severe hypoglycemia. However, the proportion and clinical characteristics of type 2 diabetic patients who fail to show appropriate cortisol and/or growth hormone secretion in response to severe hypoglycemia have not been investigated.Methods: We measured the plasma cortisol and growth hormone levels in type 2 diabetes with severe hypoglycemia (defined as blood ...

ea0056gp111 | Diabetes Translational | ECE2018

Olfactory receptor OR51E1 mediates GLP-1 secretion in enteroendocrine L cells

Ku Cheol Ryong , Han Ye Eon , Kim Daham , Hong Jae Won , Kim Sun Ho , Lee Eun Jig

Few studies have investigated the intracellular signaling pathways mediating the effects of glucagon-like peptide-1 (GLP-1) secretagogues in enteroendocrine L cells. Specific receptors, channels, and intracellular signaling proteins expressed by the L cells have only begun to be characterized. The present study aimed to investigate the role of the olfactory receptor (OR) OR51E1 in GLP-1 secretion. We verified the expression of olfactory marker protein (OMP), an indicator of OR...

ea0056gp194 | Pituitary Basic | ECE2018

Olfactory marker protein regulates prolactin secretion and production by modulating Ca2+ and TRH signaling in lactotrophs

Ku Cheol Ryong , Kang Chan Woo , Kim Daham , Hong Jae Won , Kim Sun Ho , Lee Eun Jig

Olfactory marker protein (OMP) is a marker of olfactory receptor-mediated chemoreception, even outside the olfactory system. Here, we report that OMP expression in the pituitary gland plays a role in basal and thyrotropin-releasing hormone (TRH)-induced prolactin (PRL) production and secretion. We found that OMP was expressed in human and rodent pituitary glands, especially in PRL-secreting lactotrophs. OMP knockdown in GH4 rat pituitary cells increased PRL production and secr...

ea0056p806 | Pituitary - Clinical | ECE2018

Association between prolactin level and tumor size reduction at 3 months after cabergoline treatment in patients with macroprolactinoma

Kim Daham , Lee Youngki , Park Se Hee , Park Kyeong Hye , Ryong Ku Cheol , Kim Sun Ho , Lee Eun Jig

Objectives: Prolactin (PRL) normalization after 3 months of Cabergoline (CAB) treatment are useful predictors of responsiveness in patients with prolactinoma. However, differences within the PRL normalization cut-off value have not been identified.Methods: We reviewed the medical records of patients with prolactinomas who were treated with CAB as a primary drug at Severance Hospital. We included patients who had a full dataset of pituitary hormone assays...

ea0094p171 | Adrenal and Cardiovascular | SFEBES2023

A clinical case demonstrating the challenges in diagnosing and managing Paraneoplastic Cushing’s Syndrome

Iqbal Zohaib , Ho Jan , Walker Leanne , White Ann , Monaghan Philip , Thirkettle Sally , Gulamhusein Aziz , Keevil Brian , Mansoor Wasat , Adam Safwaan

We present a case of a 62-year-old lady with a grade 3 well-differentiated metastatic gastric-neuroendocrine tumour complicated by symptoms of CS (weight-gain, bruising, proximal weakness) which developed over 4 weeks. She had progressive disease after exhausting all conventional anti-neoplastic therapeutic options. Screening tests revealed raised 24-h urinary free cortisol (3460 nmol/24h[<165]), post-overnight dexamethasone suppression serum cortisol (serF) 1200 nmol/l(&#...